Regorafenib, a TKI with a broad range of targets including VEGF-receptor, epidermal growth factor receptor, platelet-derived growth factor receptor and fibroblast growth factor receptor, has shown anti-immunosuppressive properties and promotes anti-tumor immunity by modulating macrophages and increasing the proliferation and activation of CD8+ T cells (26). Here, EGFR is linked to neoplasm.